Renal tubular acidosis: types, causes, and the AU management approach

What renal tubular acidosis is

Renal tubular acidosis (RTA) is a group of tubular transport disorders characterised by normal anion gap (hyperchloraemic) metabolic acidosis from impaired renal acid excretion or bicarbonate reabsorption. Unlike the high anion gap acidosis of diabetic ketoacidosis or lactic acidosis, RTA produces an acidosis where the anion gap is normal — the kidneys are retaining chloride in exchange for failing to excrete acid or retain bicarbonate, explaining the hyperchloraemia.

The key distinction from chronic kidney disease acidosis is that RTA occurs with relatively preserved glomerular filtration relative to the degree of acidosis. Advanced CKD produces acidosis because there is simply insufficient functioning nephron mass; in RTA, the glomeruli are adequately working but the tubules have specific transport defects.

Three types are clinically relevant in Australian general practice:

• Type 1 (distal RTA) — failure of the distal nephron to excrete hydrogen ions; produces hypokalaemia and alkaline urine despite systemic acidaemia.
• Type 2 (proximal RTA) — failure of the proximal tubule to reabsorb filtered bicarbonate; produces hypokalaemia and Fanconi syndrome.
• Type 4 (hyperkalaemic distal RTA) — aldosterone deficiency or resistance; produces hyperkalaemia and is the most common type seen in general practice.

A. Core clinical — the AU general-practice framework

Distinguishing the types at the bedside

The Goldstein urine anion gap approach uses a simple calculation — urine sodium plus urine potassium minus urine chloride — to estimate renal ammonium excretion. A positive urine anion gap reflects failed ammonium excretion and indicates RTA; a negative urine anion gap indicates preserved ammonium excretion and suggests gastrointestinal bicarbonate loss (such as diarrhoea) as the cause.

Type 1 (distal RTA):

• Serum potassium low (hypokalaemia)
• Urine pH >5.5 despite systemic acidaemia — the α-intercalated cell V-ATPase or AE1 exchanger is dysfunctional, preventing urinary acidification
• Nephrocalcinosis and calcium phosphate stones from hypocitraturia and hypercalciuria
• Osteomalacia from chronic acidaemia mobilising bone mineral
• Common causes in adults: Sjögren syndrome (present in ~25% of adult Type 1 presentations — Pereira CJASN 2009); also autoimmune hepatitis, primary biliary cholangitis, SLE, RA, sarcoidosis, medullary sponge kidney; drugs — amphotericin B, lithium, ifosfamide, topiramate

Type 2 (proximal RTA):

• Serum potassium low (hypokalaemia)
• Serum bicarbonate stabilises at 12–18 mmol/L (steady state when tubular threshold is reached)
• Urine pH variable — often below 5.5 once serum bicarbonate falls to the new threshold
• Fanconi syndrome — glycosuria with normal blood glucose, aminoaciduria, phosphaturia causing hypophosphataemia, uricosuria, low-molecular-weight proteinuria
• Common causes in adults: multiple myeloma with light-chain cast nephropathy (multiple myeloma); tenofovir disoproxil fumarate (TDF) — switch to tenofovir alafenamide (TAF) when Fanconi is detected (Mayer NEJM 2017); Wilson disease; ifosfamide; heavy metals

Type 4 (hyperkalaemic distal RTA):

• Serum potassium high (hyperkalaemia)
• Mild acidosis (bicarbonate 17–22 mmol/L)
• Urine pH typically <5.5 — urinary acidification is preserved; the defect is impaired ammoniagenesis driven by low aldosterone and hyperkalaemia
• The most common RTA in Australian general practice — essentially ubiquitous in diabetic CKD on RAS-blocking drugs
• Causes: diabetic nephropathy with hyporeninaemic hypoaldosteronism; ACE inhibitors, ARBs, direct renin inhibitors; MRAs (spironolactone, eplerenone); NSAIDs; calcineurin inhibitors; trimethoprim (blocks ENaC); heparin; adrenal insufficiency; chronic urinary tract obstruction

History

• Type 1 symptoms — weakness, fatigue, polyuria, polydipsia, muscle cramps; hypokalaemic flaccid paralysis (can mimic Guillain-Barré); bone pain and pathological fractures; recurrent calcium-phosphate kidney stones.
• Type 2 symptoms — similar muscular features and rickets or osteomalacia from phosphate wasting; growth failure in children.
• Type 4 — often initially asymptomatic; the clinical clue is persistent hyperkalaemia in diabetic CKD or on RAS-blocking drugs.
• Risk factors to screen — diabetes with CKD, autoimmune disease (ask about dry eyes and dry mouth pointing to Sjögren syndrome), known myeloma or MGUS, tenofovir or ifosfamide exposure, lithium prescribing.
• Family history — hereditary forms exist (autosomal dominant and recessive); deafness in the family may indicate an ATP6V1B1/ATP6V0A4 mutation.

Examination

• Musculoskeletal — proximal muscle weakness, bone tenderness, Looser zones on X-ray (osteomalacia), skeletal deformity.
• Neurological — symmetric flaccid weakness and depressed reflexes in severe hypokalaemia.
• Cardiovascular — blood pressure (hypertension common in Type 4); arrhythmia from potassium disturbance.
• Eyes and mouth — Schirmer test for dry eyes; salivary gland enlargement; dental caries (Sjögren syndrome).
• Other — Kayser-Fleischer rings on slit lamp (Wilson disease causing Type 2); hepatomegaly (autoimmune hepatitis, Wilson disease).

Investigations

• First-line bloods — serum UEC (particularly potassium, chloride, bicarbonate); albumin-corrected anion gap; fasting glucose (to exclude DKA); calcium, phosphate, magnesium, urate.
• Urine — fresh midstream urine pH (measure promptly; stale specimens drift alkaline due to urea-splitting organisms); urine electrolytes (sodium, potassium, chloride) for the urine anion gap; urine glucose; urine beta-2 microglobulin and fractional excretion of phosphate if Fanconi syndrome is suspected.
• Type 4 workup — paired morning fasting plasma aldosterone and renin (ideally after 30 minutes upright); cortisol and ACTH stimulation test if Addison disease is suspected.
• Type 1 autoimmune workup — ANA, ENA panel including anti-Ro/SSA and anti-La/SSB (Sjögren syndrome), anti-dsDNA (SLE), RF and anti-CCP (RA), ANCA, cryoglobulins.
• Type 2 paraprotein screen — serum protein electrophoresis, immunofixation, serum free light chains; urinary Bence Jones protein.
• Imaging — renal ultrasound for nephrocalcinosis (medullary calcification in Type 1), nephrolithiasis, hydronephrosis (obstruction as cause of Type 4), or polycystic kidneys.
• DEXA at diagnosis if osteomalacia or chronic acidosis is present.

B. Evidence appraisal — treatment principles

Alkali therapy for Types 1 and 2

Potassium citrate (Polycitra-K, Urocit-K) is preferred over sodium bicarbonate for Type 1 dRTA with stone disease, because it simultaneously corrects the hypokalaemia, alkalinises urine, and raises urinary citrate to inhibit calcium-phosphate stone formation. Hydrochlorothiazide 12.5–25 mg daily can be added as an adjunct to reduce hypercalciuria in stone-forming patients (Borghi NEJM 2002) — though caution is needed as thiazides worsen hypokalaemia and require potassium citrate cover.

For Type 2 proximal RTA, alkali doses must be much larger (5–15 mmol/kg/day) because each dose of bicarbonate given is promptly lost in the urine. Potassium chloride is preferred over potassium citrate once bicarbonate replacement is under way.

Palatability and adherence are the dominant treatment failure mechanisms for Types 1 and 2. Shohl’s solution and multiple daily tablets are challenging long-term; the pharmacist and dietitian are valuable members of the care team.

Type 4 management

Management is primarily drug rationalisation. Review every medication contributing to hyperkalaemia — NSAIDs, trimethoprim, potassium-sparing diuretics (spironolactone, eplerenone), calcineurin inhibitors, and heparin. Low-potassium dietary guidance with dietitian input is important.

Novel potassium binders — patiromer (Veltassa) and sodium zirconium cyclosilicate (Lokelma) — are PBS Authority-listed for chronic hyperkalaemia in CKD on RAS-blocking drugs (Weir NEJM 2015; Packham NEJM 2015). These enable continued RAS blockade — important for cardiorenal protection — in patients who would otherwise require dose reduction or cessation due to hyperkalaemia.

Fludrocortisone 0.05–0.2 mg daily is appropriate when Type 4 is driven by primary adrenal insufficiency (Addison disease) or true hyporeninaemic hypoaldosteronism.

Treating the underlying cause

For Sjögren-associated Type 1 RTA — hydroxychloroquine provides modest immunomodulation and sicca symptom benefit (Carsons Arthritis Care Res 2017); treat with rheumatology input.

For tenofovir-disoproxil-associated Type 2 RTA (Fanconi syndrome) — switch to tenofovir alafenamide (TAF) when Fanconi syndrome is detected. Mayer NEJM 2017 demonstrated substantially lower renal toxicity with TAF.

For myeloma-associated Type 2 RTA — refer to haematology for chemotherapy or autologous stem cell transplant. RTA may improve significantly with disease control.

C. Monitoring and long-term follow-up

All patients with confirmed RTA benefit from the following monitoring framework, per Kidney Health Australia / KHA-CARI guidelines and eTG:

• Stable on therapy — serum UEC, calcium, phosphate, magnesium, and bicarbonate every three months initially, then six-to-twelve monthly when stable.
• Renal ultrasound annually for nephrocalcinosis and stone surveillance in Type 1.
• DEXA at diagnosis and every two years if osteomalacia or chronic acidosis is established.
• Urine pH and urine calcium and citrate at each review in Type 1.
• Eye and dental review annually if Sjögren syndrome is the underlying cause.
• Pregnancy planning — pre-conception nephrology and obstetric review; alkali requirements increase during pregnancy.

Adherence should be reviewed at every visit. The most common cause of treatment failure is poor palatability of alkali preparations leading to missed doses.

D. Australian operations

MBS items

• GP consultations — items 23 / 36 / 44.
• Pathology — UEC, calcium, phosphate, magnesium — rebatable under the episode-of-care pathology items; urinalysis and urine pH under 69333; urine biochemistry (urine electrolytes for UAG) under 66509 / 66516.
• Aldosterone and renin (paired) — 71178, typically specialist-initiated.
• Autoantibody screen (ANA, ENA, anti-Ro/SSA, ANCA) — the 71161 family.
• SPEP, immunofixation, serum free light chains — 66719 / 66721 / 66705.
• Renal ultrasound — 55054.
• DEXA — 12306 when criteria for rebate are met.
• GP Chronic Condition Management Plan — items 965 / 967; RTA is a typical chronic disease management indication especially with CKD overlay.
• ATSI health assessment — item 715; CKD and RTA are prevalent in ATSI populations.
• Telehealth — items 91790 / 91891.

PBS medicines

• Sodium bicarbonate 500 mg and 840 mg tablets — PBS general schedule.
• Potassium citrate (Polycitra-K, Urocit-K) — PBS Authority Required for chronic hypokalaemic urolithiasis and RTA.
• Potassium chloride (Slow K, Span K) — PBS Authority Required for documented hypokalaemia.
• Hydrochlorothiazide and indapamide — PBS general schedule.
• Furosemide — PBS general schedule.
• Fludrocortisone (Florinef) 0.1 mg — PBS Authority Required for documented mineralocorticoid deficiency.
• Patiromer (Veltassa) — PBS Authority Required for chronic hyperkalaemia in CKD on RAS blockade.
• Sodium zirconium cyclosilicate (Lokelma) — PBS Authority Required; equivalent indication.
• Hydroxychloroquine — PBS Authority for autoimmune rheumatic disease; requires baseline and annual retinal screening.
• Tenofovir alafenamide (Vemlidy) — PBS for hepatitis B; combination products (Descovy, Biktarvy) — PBS Section 100 for HIV.

E. Special populations

Children — Growth failure is a hallmark of inadequately treated paediatric RTA. Adequate alkali correction enables catch-up growth. Hereditary autosomal recessive Type 1 RTA — particularly with mutations in ATP6V1B1 or ATP6V0A4 — is associated with sensorineural hearing loss: assess hearing in any child with RTA. Paediatric nephrology referral is mandatory for all confirmed paediatric cases.

Pregnancy — Alkali therapy is safe and necessary during pregnancy; uncorrected acidosis worsens foetal growth. Sodium bicarbonate, potassium citrate, and fludrocortisone are pregnancy-compatible. ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists are contraindicated in pregnancy — switch antihypertensive regimens with obstetric input.

ATSI populations — Higher CKD prevalence means Type 4 RTA is more commonly encountered. Closing the Gap PBS co-payment applies. Culturally safe communication about chronic alkali therapy, dietary potassium restriction, and kidney monitoring is essential.

Hereditary RTA — Genetic testing (for SLC4A1, ATP6V1B1, ATP6V0A4, SLC4A4) is appropriate for paediatric autosomal recessive presentations and family-clustered cases. Refer to clinical genetics for cascade family screening; counsel about insurance moratorium provisions for predictive genetic testing under FSC Standard No. 11A.

When to escalate

Refer or escalate when:

• Nephrology — all confirmed RTA at diagnosis; recurrent stones; declining eGFR; refractory potassium disturbance; suspected hereditary RTA.
• Emergency — pH <7.20; hypokalaemic flaccid paralysis; rhabdomyolysis; new AKI; anuria; severe arrhythmia.
• Rheumatology — suspected Sjögren syndrome, SLE, or RA as underlying cause.
• Haematology — suspected myeloma or other haematological malignancy.
• Endocrinology — adrenal insufficiency; primary aldosteronism workup for Type 4.
• Clinical genetics — hereditary forms, paediatric cases, family screening.

What this article is and is not

This is general health information drawn from current Australian and international nephrology guidelines — Kidney Health Australia / KHA-CARI, eTG Nephrology, AMH, RACGP CKD resources, and leading peer-reviewed nephrology references. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about investigation, treatment, and specialist referral are made with your own GP and treating clinicians.

For consumer-friendly resources: Kidney Health Australia patient resources, HealthDirect, and Better Health Channel.

---

Sources cited

1. Kidney Health Australia / KHA-CARI Guidelines
2. Therapeutic Guidelines (eTG) — Nephrology and electrolyte disorders
3. RACGP — Chronic kidney disease management in general practice
4. Australian Medicines Handbook
5. Wagner CA, Mohebbi N — Renal tubular acidosis (Nat Rev Nephrol 2010)
6. Pereira PCB et al — Renal involvement in primary Sjögren’s syndrome (CJASN 2009)
7. Goldstein MB et al — Urine anion gap and ammonium excretion (NEJM 1986)
8. Preminger GM et al — Potassium citrate for calcium stone prevention (NEJM 1985)
9. Borghi L et al — Dietary and pharmacological stone prevention (NEJM 2002)
10. Mayer KH et al — Tenofovir alafenamide vs tenofovir disoproxil fumarate (NEJM 2017)
11. Carsons SE et al — Treatment guidelines for Sjögren’s syndrome (Arthritis Care Res 2017)
12. Weir MR et al — Patiromer in CKD with hyperkalaemia (NEJM 2015)
13. Packham DK et al — Sodium zirconium cyclosilicate in hyperkalaemia (NEJM 2015)
14. HealthDirect — Kidney disease
15. Kidney Health Australia — Patient resources